BioSpace News Archive

According to Vision Research Reports, the global Cancer Biopsy market size is estimated to hit around US$ 40.65 billion by 2030 from valued at US$ 21.8 billion in 2020, growing at a CAGR of 10.35% from 2021 to 2030.

Centene Corporation will host its next Investor Meeting in a virtual format on Friday, June 17th, 2022.

The Menarini Group (“Menarini”) and Radius Health, Inc. (“Radius”) (NASDAQ: RDUS) (collectively, the “Companies”) today announced that data from the pivotal phase 3 EMERALD clinical trial (NCT03778931) evaluating elacestrant as a monotherapy vs. standard of care (SOC; fulvestrant or aromatase inhibitor, AI) for the treatment of ER+/HER2- advanced or metastatic breast cancer were published in the Journal of Clinical Oncology.

Sonendo, Inc., a leading dental technology company and developer of the GentleWave® System, announced that management will be participating in the upcoming Stifel Jaws and Paws Conference.

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that it received notification of Bayer’s intention to end the exclusive worldwide licensing agreement for next-generation mesothelin-directed CAR T-cell therapies.

Leica Biosystems is launching BOND-PRIME, a premium Advanced Staining solution, to advance diagnostic productivity in the lab.

ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today reported financial and operating results for the first quarter ended March 31, 2022 and provided a corporate strategic update.

The global Virtual Clinical Trials market size is estimated to reach around US$ 21.5 billion by 2030 from valued at US$ 8.4 billion in 2020, growing at a CAGR of 6.7% over the forecast period 2021 to 2030.

The global endoscopy devices market size is estimated to surpass around US$ 72.9 billion by 2030 and it is expected to grow at a CAGR of 9.3% over the forecast period 2021 to 2030.

According to Report, the Clinical Trial Supplies market size is estimated to surpass around US$ 13.3 billion by 2030 and is expected to registered growth at a CAGR of 17.3% from 2021 to 2030.